U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07641010) titled 'PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma' on June 05.
Brief Summary: A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Hodgkin Lymphoma
Intervention:
DRUG: PD-1+JAK1i
PD-1 inhibitor: 3 mg/kg, IV, D1, 22; JAK1i: 4mg/m2, PO, QD, D1-35;
DRUG: PD-1
PD-1 inhibitor: 3 mg/kg, IV, D1, 22;
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Jiao Tong University School of Medicine
Information pr...